Your browser is no longer supported. Please, upgrade your browser.
Settings
NKTR Nektar Therapeutics daily Stock Chart
NKTR [NASD]
Nektar Therapeutics
Index- P/E- EPS (ttm)-2.44 Insider Own1.30% Shs Outstand175.40M Perf Week-7.32%
Market Cap3.82B Forward P/E- EPS next Y-2.45 Insider Trans-13.38% Shs Float173.87M Perf Month2.11%
Income-425.40M PEG- EPS next Q-0.68 Inst Own- Short Float16.90% Perf Quarter26.57%
Sales120.60M P/S31.66 EPS this Y289.50% Inst Trans-0.31% Short Ratio10.44 Perf Half Y-32.22%
Book/sh8.49 P/B2.56 EPS next Y3.90% ROA-20.00% Target Price32.85 Perf Year-50.47%
Cash/sh8.53 P/C2.55 EPS next 5Y-7.30% ROE-26.60% 52W Range15.64 - 47.11 Perf YTD0.86%
Dividend- P/FCF- EPS past 5Y36.30% ROI34.90% 52W High-53.79% Beta2.59
Dividend %- Quick Ratio12.50 Sales past 5Y51.60% Gross Margin81.10% 52W Low39.24% ATR1.42
Employees618 Current Ratio12.60 Sales Q/Q5.00% Oper. Margin- RSI (14)47.08 Volatility4.54% 5.78%
OptionableYes Debt/Eq0.17 EPS Q/Q-1.20% Profit Margin- Rel Volume0.57 Prev Close22.13
ShortableYes LT Debt/Eq0.17 EarningsFeb 05 AMC Payout- Avg Volume2.82M Price21.77
Recom2.40 SMA20-4.07% SMA501.67% SMA200-13.92% Volume1,593,475 Change-1.63%
Oct-24-19Initiated Oppenheimer Perform $18
Oct-08-19Downgrade Goldman Buy → Sell $54 → $16
Aug-09-19Downgrade Mizuho Buy → Neutral $79 → $21
Aug-09-19Downgrade JP Morgan Overweight → Neutral $62 → $33
Aug-09-19Downgrade Jefferies Buy → Hold $59 → $23
Mar-15-19Initiated SVB Leerink Mkt Perform $38
Dec-13-18Initiated Goldman Buy $62
Jun-11-18Downgrade H.C. Wainwright Buy → Neutral $54
Jun-04-18Reiterated H.C. Wainwright Buy $125 → $97
Apr-20-18Initiated Seaport Global Securities Buy $120
Apr-13-18Resumed Piper Jaffray Overweight $125
Apr-06-18Reiterated Mizuho Buy $89 → $103
Apr-02-18Resumed H.C. Wainwright Buy $125
Mar-02-18Reiterated Canaccord Genuity Buy $80 → $94
Jan-22-18Reiterated Mizuho Buy $45 → $89
Nov-13-17Reiterated Mizuho Buy $30 → $45
Nov-13-17Reiterated Canaccord Genuity Buy $35 → $50
Nov-09-17Initiated Canaccord Genuity Buy $35
Aug-17-17Initiated Evercore ISI In-line $20
Aug-07-17Initiated H.C. Wainwright Buy $31
Jan-23-20 11:43AM  Nektar Therapeutics Pullback May Be Short-Lived Schaeffer's Investment Research
Jan-21-20 05:53PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR GlobeNewswire
Jan-16-20 01:37PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR GlobeNewswire
Jan-15-20 04:08PM  How An FDA Committee Pulled The Rug Out From This Highflying Biotech Investor's Business Daily -15.99%
10:27AM  Nektar's Pain Drug Gets Adverse Advisory Committee Decision Zacks
10:23AM  Its opioid dissed by FDA advisors, S.F. drugmaker abandons program American City Business Journals
09:17AM  Benzinga Pro's Top 5 Stocks To Watch For Wed., Jan. 15, 2020: GS, RSX, NKTR, NVAX, ACB Benzinga
08:22AM  The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance Benzinga
07:30AM  Nektar Stock Plunges 15% as FDA Panel Rejects Opioid Painkiller Barrons.com
04:44AM  Nektar Squeezed as FDA Rejects Opioid Addiction-Fighting Drug TheStreet.com
Jan-14-20 10:47PM  Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol PR Newswire
06:27PM  Nektar stock drops more than 10% as FDA advisers say no to painkiller MarketWatch
10:49AM  'Unlikeable' opioid from Nektar faces FDA pain point American City Business Journals
05:00AM  Top Picks 2020- Nektar Therapeutics NKTR MoneyShow
Jan-13-20 09:14AM  Nektar Up 25% as Bristol-Myers Expands Bempeg Collaboration Zacks
Jan-10-20 04:08PM  Why Bristol's Vote Of Confidence Sent This Biotech Stock Rocketing Investor's Business Daily +24.69%
02:32PM  Shareholder Alert: Robbins LLP Reminds Investors Nektar Therapeutics (NKTR) Sued for Misleading Shareholders Business Wire
01:34PM  Nektar Therapeutics Options Pop as Stock Soars Schaeffer's Investment Research
08:01AM  Nektar Therapeutics, Bristol-Myers Expand Effort to Develop Treatment for Cancer TheStreet.com
06:59AM  Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab) Business Wire
Jan-07-20 09:00AM  Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA PR Newswire
Dec-24-19 01:09PM  Why A Bidding War For Synthorx Bodes Well For This Biotech Stock Investor's Business Daily
10:10AM  Trade Deal Optimism Fuels Santa Rally: ETFs & Stocks to Bet On Zacks
Dec-19-19 12:21PM  10 Stocks That Could Be Tax-Loss Buying Opportunities Benzinga
08:59AM  5 Losing Stocks From 2019 to Rebound Next Year Zacks
Dec-17-19 09:00AM  Nektar Therapeutics Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D. PR Newswire
Dec-10-19 07:49PM  Is Nektar Therapeutics (NKTR) A Good Stock To Buy? Insider Monkey
05:00AM  Introducing Nektar Therapeutics (NASDAQ:NKTR), A Stock That Climbed 84% In The Last Three Years Simply Wall St.
Dec-09-19 10:05AM  Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting PR Newswire +13.03%
Dec-06-19 11:31AM  Why Is Nektar (NKTR) Up 6.2% Since Last Earnings Report? Zacks
Dec-03-19 09:00AM  Nektar Appoints John Northcott as Chief Commercial Officer PR Newswire
Nov-13-19 05:30PM  Nektar to Webcast Presentation at Jefferies 2019 London Healthcare Conference PR Newswire
Nov-12-19 11:11PM  Edited Transcript of NKTR earnings conference call or presentation 6-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
09:33AM  Company News For Nov 12, 2019 Zacks
Nov-11-19 04:25PM  Can This Biotech Improve On Bristol-Myers' Blockbuster Cancer Drug? Investor's Business Daily
08:55AM  Nektar Therapeutics Stock Is Rising on Test Data for Cancer Drug Barrons.com
Nov-10-19 11:00AM  Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology PR Newswire
Nov-09-19 05:30PM  Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting PR Newswire
Nov-07-19 11:13AM  Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up Zacks
Nov-06-19 06:15PM  Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:03PM  Nektar Therapeutics Reports Financial Results for the Third Quarter of 2019 PR Newswire
Nov-03-19 10:51AM  The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight Benzinga
Nov-01-19 09:00AM  Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialist for Analysts & Investors During 2019 Society for Immunotherapy of Cancer 34th Annual Meeting PR Newswire +6.92%
Oct-30-19 05:00PM  Nektar to Announce Financial Results for the Third Quarter 2019 on Wednesday, November 6, 2019, After Close of U.S.-Based Financial Markets PR Newswire
10:34AM  Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Oct-28-19 07:46PM  Is Nektar Therapeutics (NKTR) Going To Burn These Hedge Funds ? Insider Monkey +6.12%
Oct-25-19 06:00AM  With Good Trial Results, Nektar Therapeutics Could "Turn on a Dime" MoneyShow
Oct-23-19 03:26PM  16 Stocks With The Highest Long-Term Sales Growth Rate Benzinga
Oct-18-19 03:00PM  DEADLINE ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: October 18, 2019 GlobeNewswire
10:07AM  FINAL DEADLINE ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: October 18, 2019 ACCESSWIRE
Oct-17-19 01:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR ACCESSWIRE
11:18AM  KESSLER TOPAZ MELTZER & CHECK, LLP: Final Deadline Reminder for NEKTAR THERAPEUTICS Investors NKTR GlobeNewswire
Oct-16-19 06:03PM  FINAL DEADLINE APPROACHING: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics Business Wire
10:11AM  NKTR CLASS ACTION DEADLINE IN 1 DAY: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Motion for Lead Plaintiff in a Securities Class Action Lawsuit Against Nektar Therapeutics Business Wire
10:06AM  DEADLINE ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: October 18, 2019 ACCESSWIRE
09:00AM  Nektar Therapeutics Announces Initiation of First-in-Human Phase 1 Clinical Study of NKTR-255, an IL-15 Agonist, in Adults with Relapsed or Refractory Non-Hodgkin Lymphoma or Multiple Myeloma PR Newswire
Oct-15-19 08:49PM  DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics, Inc. (NASDAQ: NKTR) and Encourages Nektar Investors to Contact the Firm Business Wire +8.98%
05:55PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR GlobeNewswire
05:18PM  INVESTOR DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics ACCESSWIRE
Oct-12-19 08:03AM  Does Nektar Therapeutics (NASDAQ:NKTR) Have A Healthy Balance Sheet? Simply Wall St.
06:50AM  CLASS ACTION DEADLINES: Brodsky & Smith, LLC Reminds Investors of Approaching Deadlines Related to the Following Companies: VAL, NKTR and NTAP ACCESSWIRE
Oct-11-19 06:05PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR ACCESSWIRE +5.95%
03:00PM  DEADLINE ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: October 18, 2019 GlobeNewswire
10:05AM  INVESTOR ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies of Class Action and Lead Deadline: October 18, 2019 ACCESSWIRE
06:40AM  CLASS ACTION DEADLINES: Brodsky & Smith, LLC Reminds Investors of Deadlines to File Lead Plaintiff Motions Related to the Following Companies: NTAP, NKTR and VAL ACCESSWIRE
Oct-10-19 07:39PM  SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics GlobeNewswire
10:04AM  INVESTOR ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: October 18, 2019 ACCESSWIRE
06:15AM  CLASS ACTION UPDATE: Brodsky & Smith, LLC Reminds Investors of Important Class Action Deadlines Related to the Following Companies: NTAP, NKTR and VAL ACCESSWIRE
Oct-09-19 11:19AM  INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in ERI, NKTR, and GVA of Filing Deadlines GlobeNewswire
11:10AM  Nektar's Shares Drop on Rating Downgrade by Goldman Sachs Zacks
11:05AM  ROSEN, A TOP RANKED LAW FIRM, Reminds Nektar Therapeutics Investors of Important October 18th Deadline in Securities Class Action NKTR GlobeNewswire
11:00AM  Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics GlobeNewswire
08:00AM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NetApp, SAExploration, Nektar Therapeutics, and Valaris and Encourages Investors to Contact the Firm GlobeNewswire
06:58AM  CLASS ACTION DEADLINES: Brodsky & Smith, LLC Reminds Investors of Approaching Deadlines Related to the Following Companies: NKTR, VAL and NTAP ACCESSWIRE
Oct-08-19 04:20PM  OCTOBER 18 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE -13.34%
02:00PM  Nektar Hit With Double Downgrade From Goldman: 'Significant Challenges In Rebuilding Confidence' Benzinga
01:29PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR GlobeNewswire
01:12PM  [video]Nektar Shares Drop After Double Downgrade to Sell at Goldman Sachs TheStreet.com
09:42AM  Goldman Throws in the Towel on Nektar After $14 Billion Drop Bloomberg
08:23AM  Nektar Therapeutics shares slide 6.3% premarket after Goldman downgrades to sell from buy MarketWatch
06:15AM  CLASS ACTION DEADLINES: Brodsky & Smith, LLC Reminds Investors of Looming Deadlines Related to the Following Companies: VAL, NKTR and NTAP ACCESSWIRE
Oct-07-19 09:20PM  SHAREHOLDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
11:28AM  NKTR CLASS ACTION DEADLINE IN 11 DAYS: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Motion for Lead Plaintiff in a Securities Class Action Lawsuit Against Nektar Therapeutics ACCESSWIRE
11:00AM  Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics GlobeNewswire
10:03AM  INVESTOR ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: October 18, 2019 ACCESSWIRE
09:00AM  Nektar Therapeutics Announces Initiation of Two Clinical Studies of Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Psoriasis and Atopic Dermatitis PR Newswire
06:30AM  CLASS ACTION DEADLINES: Brodsky & Smith, LLC Reminds Investors of Approaching Deadlines Related to the Following Companies: NKTR, NTAP and VAL ACCESSWIRE
Oct-04-19 05:46PM  KESSLER TOPAZ MELTZER & CHECK, LLP - DEADLINE REMINDER FOR NEKTAR THERAPEUTICS INVESTORS ACCESSWIRE
03:00PM  Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS) & Burford Capital Limited (BRFRF, BRFRY) Bronstein, Gewirtz & Grossman, LLC Reminds of Class Actions GlobeNewswire
10:17AM  Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS) & Burford Capital Limited (BRFRF, BRFRY) Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action Deadlines ACCESSWIRE
06:11AM  CLASS ACTION DEADLINES: Brodsky & Smith, LLC Reminds Investors of Approaching Deadlines Related to the Following Companies: NKTR, NTAP and VAL ACCESSWIRE
Oct-03-19 01:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR ACCESSWIRE +5.02%
11:35AM  Zhang Investor Law Reminds Investors of October 18 Deadline in Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR GlobeNewswire
11:35AM  European and US Markets Decline Sharply on Wednesday GuruFocus.com
06:05AM  CLASS ACTION UPDATE: LAW OFFICE OF Brodsky & Smith, LLC Reminds Investors of Lead Plaintiff Deadline in Class Action Against NEKTAR THERAPEUTICS (NASDAQ: NKTR) ACCESSWIRE
Oct-02-19 09:18PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NetApp, SAExploration, Nektar Therapeutics, and Valaris and Encourages Investors to Contact the Firm GlobeNewswire -5.97%
01:46PM  NKTR CLASS ACTION DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Motion for Lead Plaintiff in a Securities Class Action Lawsuit Against Nektar Therapeutics ACCESSWIRE
11:00AM  Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics GlobeNewswire
10:15AM  Nektar Therapeutics (NKTR), Pluralsight, Inc. (PS) & Burford Capital Limited (BRFRF, BRFRY) Bronstein, Gewirtz & Grossman, LLC Reminds of Class Actions ACCESSWIRE
10:12AM  INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in ERI, NKTR, and GVA of Filing Deadlines GlobeNewswire
Nektar Therapeutics develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for solid tumors; and NKTR-255, which is in preclinical stage for immuno-oncology. In addition, the is developing ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain; CIMZIA for crohn's disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia associated with chronic kidney disease. Further, it is developing Macugen for age-related macular degeneration; Somavert for acromegaly; Neulasta for neutropenia; Dapirolizumab Pegol for systemic lupus erythematosus; PEGPH20 for pancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Halozyme Therapeutics, Inc.; Bristol-Myers Squibb Company; Baxalta Incorporated; and Eli Lilly and Company, as well as with Merck KGaA and Pfizer Inc. Nektar Therapeutics also has a research collaboration with Trovagene, Inc. for the treatment of metastatic colorectal cancer. Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WHITFIELD ROY ADirectorDec 18Option Exercise9.2410,00092,400198,250Dec 20 06:31 PM
Zalevsky JonathanChief R&D OfficerNov 18Sale17.973,96071,161291,697Nov 20 07:07 PM
ROBIN HOWARD WPresident & CEONov 18Sale17.9713,556243,601299,219Nov 20 07:05 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerNov 18Sale17.972,71348,753160,441Nov 20 07:06 PM
Labrucherie Gil MSVP, COO & CFONov 18Sale17.978,863159,268219,009Nov 20 07:04 PM
Labrucherie Gil MSVP, COO & CFONov 13Option Exercise7.2125,000180,250252,872Nov 15 06:09 PM
Labrucherie Gil MSVP, COO & CFONov 13Sale19.7925,000494,750227,872Nov 15 06:09 PM
ROBIN HOWARD WPresident & CEOOct 17Option Exercise7.2133,333240,331346,108Oct 17 07:00 PM
ROBIN HOWARD WPresident & CEOOct 17Sale17.6833,333589,327312,775Oct 17 07:00 PM
ROBIN HOWARD WPresident & CEOOct 16Option Exercise7.2133,334240,338346,109Oct 17 07:00 PM
ROBIN HOWARD WPresident & CEOOct 16Sale17.4833,334582,678312,775Oct 17 07:00 PM
Labrucherie Gil MSVP, COO & CFOOct 15Option Exercise7.2125,000180,250252,872Oct 17 06:59 PM
ROBIN HOWARD WPresident & CEOOct 15Option Exercise7.2133,333240,331346,108Oct 17 07:00 PM
ROBIN HOWARD WPresident & CEOOct 15Sale16.9533,333565,085312,775Oct 17 07:00 PM
Labrucherie Gil MSVP, COO & CFOOct 15Sale15.8325,000395,750227,872Oct 17 06:59 PM
Ajer Jeffrey RobertDirectorSep 30Sale18.062,37542,89322,375Oct 01 07:16 PM
Lingnau LutzDirectorSep 27Sale17.843,00053,52026,700Oct 02 07:51 PM
CHESS ROBERTDirectorSep 27Sale17.994,00071,960276,973Oct 01 07:15 PM
Ajer Jeffrey RobertDirectorSep 20Sale20.242,25045,54018,250Sep 24 06:07 PM
Labrucherie Gil MSVP & Chief Financial OfficerSep 16Option Exercise7.2125,000180,250177,872Sep 18 07:07 PM
Labrucherie Gil MSVP & Chief Financial OfficerSep 16Sale20.5225,000513,000152,872Sep 18 07:07 PM
Doberstein Stephen KSVP & Chief Scientific OfficerSep 05Buy17.2815,000259,200107,668Sep 09 05:09 PM
Labrucherie Gil MSVP & Chief Financial OfficerAug 26Option Exercise16.3130,000489,300152,872Aug 27 05:20 PM
ROBIN HOWARD WPresident & CEOAug 23Option Exercise16.3130,000489,300312,775Aug 26 05:21 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerAug 16Sale18.151,80932,833163,154Aug 19 07:09 PM
ROBIN HOWARD WPresident & CEOAug 16Sale18.1512,551227,801282,775Aug 19 07:08 PM
Labrucherie Gil MSVP & Chief Financial OfficerAug 16Sale18.155,06391,893122,872Aug 19 07:07 PM
Nicholson JohnSVP & Chief Operating OfficerAug 16Sale18.153,81969,315162,759Aug 19 07:07 PM
Doberstein Stephen KSVP & Chief Scientific OfficerAug 16Sale18.153,24558,89792,668Aug 19 07:06 PM
Labrucherie Gil MSVP & Chief Financial OfficerAug 14Option Exercise7.2125,000180,250152,935Aug 16 08:13 PM
Labrucherie Gil MSVP & Chief Financial OfficerAug 14Sale17.7925,000444,750127,935Aug 16 08:13 PM
ROBIN HOWARD WPresident & CEOJul 25Option Exercise7.2133,333240,331328,659Jul 25 08:02 PM
ROBIN HOWARD WPresident & CEOJul 25Sale29.6533,333988,323295,326Jul 25 08:02 PM
ROBIN HOWARD WPresident & CEOJul 24Option Exercise7.2133,334240,338328,660Jul 25 08:02 PM
ROBIN HOWARD WPresident & CEOJul 24Sale32.1133,3341,070,355295,326Jul 25 08:02 PM
ROBIN HOWARD WPresident & CEOJul 23Option Exercise7.2133,333240,331328,659Jul 25 08:02 PM
ROBIN HOWARD WPresident & CEOJul 23Sale32.1033,3331,069,989295,326Jul 25 08:02 PM
Labrucherie Gil MSVP & Chief Financial OfficerJul 10Option Exercise7.2125,000180,250152,935Jul 12 06:31 PM
Labrucherie Gil MSVP & Chief Financial OfficerJul 10Sale34.5725,000864,250127,935Jul 12 06:31 PM
Lingnau LutzDirectorJul 08Option Exercise9.2410,00092,40033,200Jul 10 05:34 PM
Lingnau LutzDirectorJul 08Sale34.6310,000346,30023,200Jul 10 05:34 PM
Labrucherie Gil MSVP & Chief Financial OfficerJun 17Option Exercise7.2125,000180,250152,935Jun 19 05:50 PM
Labrucherie Gil MSVP & Chief Financial OfficerJun 17Sale33.7125,000842,750127,935Jun 19 05:50 PM
ROBIN HOWARD WPresident & CEOMay 23Option Exercise7.2133,333240,331328,659May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 23Sale32.6933,3331,089,656295,326May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 22Option Exercise7.2133,334240,338328,660May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 22Sale33.3833,3341,112,689295,326May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 21Option Exercise7.2133,333240,331328,659May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 21Sale32.9333,3331,097,656295,326May 23 07:19 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerMay 16Sale31.371,92860,481164,463May 17 08:22 PM
ROBIN HOWARD WPresident & CEOMay 16Sale31.3713,383419,825295,326May 17 08:22 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 16Sale31.373,767118,171127,935May 17 08:20 PM
Nicholson JohnSVP & Chief Operating OfficerMay 16Sale31.374,077127,895166,578May 17 08:21 PM
Hora ManinderSVP Pharma Dev & Mfg OpsMay 16Sale31.372,44976,82594,694May 17 08:19 PM
Doberstein Stephen KSVP & Chief Scientific OfficerMay 16Sale31.373,461108,57295,913May 17 08:18 PM
GREER R SCOTTDirectorMar 08Option Exercise5.1410,00051,400145,083Mar 12 06:18 PM
ROBIN HOWARD WPresident & CEOFeb 21Option Exercise7.2133,333240,331342,042Feb 21 08:16 PM
ROBIN HOWARD WPresident & CEOFeb 21Sale41.0133,3331,366,986308,709Feb 21 08:16 PM
ROBIN HOWARD WPresident & CEOFeb 20Option Exercise7.2133,334240,338342,043Feb 21 08:16 PM
ROBIN HOWARD WPresident & CEOFeb 20Sale43.2033,3341,440,029308,709Feb 21 08:16 PM
ROBIN HOWARD WPresident & CEOFeb 19Option Exercise7.2133,333240,331350,924Feb 21 08:16 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 19Sale42.391,80876,641166,391Feb 21 08:17 PM
Nicholson JohnSVP & Chief Operating OfficerFeb 19Sale42.393,822162,015170,655Feb 21 08:15 PM
ROBIN HOWARD WPresident & CEOFeb 19Sale42.3342,2151,787,161308,709Feb 21 08:16 PM
Labrucherie Gil MSVP & Chief Financial OfficerFeb 19Sale42.393,592152,265131,702Feb 21 08:14 PM
Hora ManinderSVP Pharma Dev & Mfg OpsFeb 19Sale42.392,386101,14397,143Feb 21 08:13 PM
Doberstein Stephen KSVP & Chief Scientific OfficerFeb 19Sale42.393,310140,31199,374Feb 21 08:13 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 04Option Exercise10.6916,119172,312184,318Feb 06 07:17 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 04Sale42.1616,119679,577168,199Feb 06 07:17 PM
Nicholson JohnSVP & Chief Operating OfficerJan 28Option Exercise10.6963,000673,470237,477Jan 30 06:02 PM
Nicholson JohnSVP & Chief Operating OfficerJan 28Sale42.8263,0002,697,660174,477Jan 30 06:02 PM